Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan

被引:8
|
作者
Sacramento Diaz-Carrasco, Maria [1 ]
Olmos, Raquel [1 ]
Blanquer, Miguel [2 ]
Velasco, Javier [1 ]
Sanchez-Salinas, Andres [2 ]
Maria Moraleda, Jose [2 ]
机构
[1] Virgen de la Arrixaca Hosp, Dept Hosp Pharm, Murcia, Spain
[2] Virgen de la Arrixaca Hosp, Dept Hematol, Murcia, Spain
关键词
Busulfan; Clonazepam; Hematopoietic stem cell transplantation; HSCT; Seizure prophylaxis; ACUTE-LEUKEMIA; CHILDREN; LORAZEPAM; PHARMACOKINETICS;
D O I
10.1007/s11096-013-9768-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Due to their favorable toxicity profile and lack of interactions, benzodiazepines have been proposed as prophylaxis of busulfan induced seizures. Although they are broadly used in pediatric patients, the experience in adults is limited. Objective To describe the effectivity for seizure prophylaxis of the fixed 1 mg every 8 h (q8h) i.v. clonazepam dosing in adult patients receiving high dose i.v busulfan, as part of the hematopoietic progenitors transplant conditioning regimen. Methods Retrospective, observational study, from January 2008 to June 2012. Patients over 15 years old that had received high dose busulfan and prophylaxis with 1 mg q8h i.v. clonazepam from 12 h before the first dose of busulfan to 24 h after the last one were selected. The primary endpoint was the occurrence of seizures until 72 h after finishing conditioning. Results Thirty-three patients, 13 female and 20 male, median age 48, were included. Autologous transplant was performed in 17 patients and allogeneic in 16. Busulfan dose was 3.2 mg/kg every 24 h with a variable duration of 2-4 days. No seizures were recorded. Conclusion The 1 mg q8h i.v. clonazepam fixed schedule is easily administered and is effective for the prevention of high dose busulfan induced seizures in adult patients.
引用
收藏
页码:339 / 343
页数:5
相关论文
共 50 条
  • [41] Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy
    Lindley, C
    Shea, T
    McCune, J
    Shord, S
    Decker, J
    Harvey, D
    Petros, WR
    Garbriel, D
    Serody, J
    Kirby, S
    Wiley, J
    ANTI-CANCER DRUGS, 2004, 15 (05) : 453 - 459
  • [42] High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors
    Diaz, MA
    Vicent, MG
    Madero, L
    BONE MARROW TRANSPLANTATION, 1999, 24 (11) : 1157 - 1159
  • [43] Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation
    R H Matthews
    M Emami
    D G Connaghan
    H K Holland
    L E Morris
    Bone Marrow Transplantation, 2007, 39 : 397 - 400
  • [44] High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors
    MA Diaz
    MG Vicent
    L Madero
    Bone Marrow Transplantation, 1999, 24 : 1157 - 1159
  • [45] Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation
    Matthews, R. H.
    Emami, M.
    Connaghan, D. G.
    Holland, H. K.
    Morris, L. E.
    BONE MARROW TRANSPLANTATION, 2007, 39 (07) : 397 - 400
  • [46] Prophylaxis in adult patients with severe haemophilia A
    Oldenburg, Johannes
    Brackmann, Hans-Hermann
    THROMBOSIS RESEARCH, 2014, 134 : S33 - S37
  • [47] Impact of Prophylactic Trimethoprim-Sulfamethoxazole on Clearance of High-Dose Methotrexate in Adult Patients
    Skoloda, Daniel
    Newman, Matthew
    Norman, Haval
    Ziggas, Jamie E.
    Ambinder, Richard F.
    JCO ONCOLOGY PRACTICE, 2024, 20 (05) : 673 - 677
  • [48] Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time
    Neroutsos, E.
    Athanasiadou, I
    Paisiou, A.
    Zisaki, K.
    Goussetis, E.
    Archontaki, H.
    Tsirigotis, P.
    Kitra, M.
    Grafakos, S.
    Spyridonidis, A.
    Dokoumetzidis, A.
    Valsami, G.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2021, 73 (10) : 1340 - 1350
  • [49] Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma
    Kondo, Eisei
    Ikeda, Takashi
    Goto, Hiroaki
    Nishikori, Momoko
    Maeda, Naoko
    Matsumoto, Kimikazu
    Kitagawa, Hideo
    Noda, Naoto
    Sugimoto, Saori
    Hara, Junichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 849 - 860
  • [50] Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT
    Berger, Karin
    Schopohl, Dorothee
    Rieger, Christina
    Ostermann, Helmut
    SUPPORTIVE CARE IN CANCER, 2015, 23 (12) : 3447 - 3454